---
document_datetime: 2026-01-16 17:40:53
document_pages: 2
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/namuscla-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: namuscla-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 1.4966505
conversion_datetime: 2026-01-17 13:03:21.433953
docling_version:
  docling-serve: 1.10.0
  docling-jobkit: 1.8.1
  docling: 2.68.0
  docling-core: 2.59.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.3
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Namuscla

Procedural steps taken and scientific information after the authorisation*

*Due to the Agency`s update of its procedure management systems, an additional document, reflecting the historical lifecycle may be available in the 'Assessment history' section. For the complete product lifecycle procedures, you may need to also refer to EPAR - Procedural steps taken and scientific information after authorisation (archive) .

| Application number                    | Scope                                                                                                                 | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary   |
|---------------------------------------|-----------------------------------------------------------------------------------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-----------|
| Variation type IA / EMA/VR/0000321349 | B.III.1.a European Pharmacopoeial Certificate of Suitability to the relevant Ph. Eur. Monograph - B.III.1.a.2 Updated | 08/01/2026                          | N/A                                         |                                  |           |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

|                                       | certificate from an already approved manufacturer - Refused                                                                                                                                                                                                                                                                                                                                                                         |            |      |                                                                               |
|---------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------|-------------------------------------------------------------------------------|
| Variation type II / EMA/VR/0000295982 | C.I HUMAN AND VETERINARY MEDICINAL PRODUCTS - C.I.4 Change(s) in the Summary of Product Characteristics, Labelling or Package Leaflet due to new quality, preclinical, clinical or pharmacovigilance data - Accepted Update of the SmPC section 4.4 of Namuscla 167 mg hard capsules to addresses the presence of potentially false positive results in urine screening for amphetamine based on internal safety signal evaluation. | 27/11/2025 | SmPC | For more information, please refer to the Summary of Product Characteristics. |